Unlock instant, AI-driven research and patent intelligence for your innovation.

Compositions and methods of treating chronic pain by administering propofol derivatives

a technology of propofol derivatives and compositions, applied in the direction of drug compositions, hydroxy compound active ingredients, antipyretics, etc., can solve the problems of limiting the utility of gabaa-r as an analgesic, and achieve the effects of enhancing gabaa-r activity, limiting its utility as analgesic, and pronounced sensitivity

Inactive Publication Date: 2019-11-28
CORNELL UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a method for treating chronic pain by using anesthtic substance called propofol or its derivatives. These derivatives have limited anesthetic properties, which make them safer for use in treating pain. The method involves administering the anesthetic substance to inhibit a specific channel called HCN1. The method can also be used to modulate the gating of this channel without enhancing another receptor called GABA-A.

Problems solved by technology

However, the general hypnotic properties of propofol resulting from its ability to allosterically enhance GABAA-R activity (Vanlersberghe et al., 2008; Franks et al., 2008; Franks, 2006; Hemmings et al., 2005; Rudolph et al., 2004; Trapani et al., 2000; Jurd et al., 2003), clearly limit its utility as an analgesic.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods of treating chronic pain by administering propofol derivatives
  • Compositions and methods of treating chronic pain by administering propofol derivatives
  • Compositions and methods of treating chronic pain by administering propofol derivatives

Examples

Experimental program
Comparison scheme
Effect test

example 1

and Methods

Materials

[0143]General chemicals used in electrophysiology were of the highest purity from Sigma Aldrich (St. Louis, Mo.) as was 2,4-di-tert-butylphenol (2,4-DTBP) (137731), 2,6-di-tert-butylphenol (2,6-DTBP) (D48400) and DHβCD (H107).

[0144]For in vitro electrophysiological experiments, Propofol (TCI America, Portland, Oreg.), 2,6-DTBP, 2,6-Di-sec-butylphenol (ACROS 152830050—obtained via Fisher Scientific), 2,4-DTBP, and 2,4-Di-sec-butylphenol (S367907, Sigma Rare Chemicals Library) were normally dissolved in DMSO at 500 mM, and then diluted in the recording solution prior to use. In some experiments, 2,6-DTBP was dissolved in 40% 2-hydroxypropyl-beta-cyclodextrin at 1% (48.5 mM) and was diluted before use in recording solution to confirm that the 2-hydroxypropyl-beta-cyclodextrin solubilized compound (as used in animal experiments) had an equivalent efficacy to the DMSO solubilized material.

[0145]2-hydroxypropyl-beta-cyclodextrin was obtained from Sigma (H107-5G and C-0...

example 2

at Therapeutically Acceptable Concentrations, Powerfully and Selectively Antagonizes the Function of HCN1 Channels

[0181]The principal effects of propofol on wild type (wt) HCN1 are recapitulated in FIGS. 2A-2D. Inspection of the TEVC current families and the corresponding tail currents obtained in the absence and presence of 20 μM propofol showed that the drug slows opening, accelerates closing and shifts gating to more hyperpolarized potentials. A fit of the Hill equation to the results from a number of such experiments shows the apparent affinity (EC50 about 7-13 μM) and maximal efficacy (ΔV1 / 2 of −35 to −45 mV) of the propofol-mediated hyperpolarization of gating (see also Cacheaux et al., 2005).

[0182]As previously reported, the slower and more cAMP sensitive HCN2 and HCN4 channels were, respectively, weakly and almost completely insensitive to the anesthetic.

[0183]With reference to FIGS. 4A-4E, the experiments showed that subanesthetic propofol alleviates at least two modalities...

example 3

ic Doses of Propofol Reduce Mechanical Allodynia and Mechanical and Thermal Hyperalgesia

[0184]FIG. 12A shows PW IPSI and PW CONTRA in post-PNL mice as a function of stimulus strength (Von Frey fibers ranging from 0.6 to 4 g) and i.p. propofol administration (cumulative dose of propofol ranging from 0 to 60 mg / kg). These doses of propofol markedly reduced the mechanical hyperalgesia observed in the ipsilateral paw with only modest disturbance of normal mechanical nociceptive response as monitored in the contralateral paw. PW IPSI was significantly higher than PW CONTRA in the absence of propofol, but the difference was significantly reduced upon administration of 20 mg / kg propofol and, at a dose of 60 mg / kg, the response becomes indistinguishable from the control value of PW CONTRA. In contrast, 20 to 60 mg / kg propofol had no statistically significant effect on PW CONTRA suggesting that in the absence of neuropathy, mechanical nociceptive reflexes are relatively insensitive to propof...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
volumeaaaaaaaaaa
thicknessaaaaaaaaaa
Login to View More

Abstract

Compositions and methods for managing or treating chronic pain are provided. More particularly, methods are provided for managing or treating chronic pain by administering to a patient in need thereof an effective amount of propofol or a propofol derivative having limited anesthetic properties. Methods of modulating HCN channel gating are also provided. Pharmaceutically acceptable compositions for, e.g., modulating HCN channel gating are further provided.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application is a divisional of U.S. application Ser. No. 13 / 389,507, filed Sep. 21, 2012, which is a National Stage of International Application No. PCT / US2010 / 045064, filed Aug. 10, 2010, which claims priority to U.S. Provisional Patent Application No. 61 / 273,912, filed Aug. 11, 2009. The entire contents of the above applications are hereby incorporated by reference as if recited in full herein.FIELD OF THE INVENTION[0002]The present invention relates to compositions and methods for managing or treating chronic pain and associated symptoms. More particularly, the present invention relates to a composition for and a method of managing or treating chronic pain including administering to a patient in need thereof an effective amount of propofol or a propofol derivative. Methods of treating or ameliorating chronic pain or modulating HCN channel gating are also provided. Pharmaceutically acceptable compositions for modulating HCN ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/05
CPCA61K31/05A61P29/00
Inventor TIBBS, GARETH R.FLOOD, PAMELAGOLDSTEIN, PETER
Owner CORNELL UNIVERSITY